This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. BD has expanded a Class I Alaris recall to cover 15 ...
To data, there have been 13 reported injuries. Becton Dickinson (BD)/Carefusion 303 is recalling the Alaris infusion pump due to incompatibility issues with Cardinal Health Monoject syringes. The Food ...
BD will pay a $175 million civil penalty to settle charges from the Securities and Exchange Commission that the company misled investors about problems with its Alaris infusion pumps. The SEC issued a ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) -The U.S. Food and Drug Administration ...
BD and its CareFusion subsidiary alerted users of potential device errors Feb. 4 and have been developing corrective software updates. (FDA) () BD is recalling hundreds of thousands of its Alaris ...
Becton, Dickinson and Company BDX, popularly known as BD, recently received the FDA’s 510(k) clearance for its updated BD Alaris Infusion System. This is expected to enable both remediation and a ...
Though the Alaris Infusion Central software doesn’t store patient health data, according to BD, hospitals using the software may choose to store other personal information in the database—which could ...
FRANKLIN LAKES, N.J., July 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the updated BD Alaris™ Infusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results